Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Medical Officer | March 12, 2026 | August 07, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Chief Medical Officer | August 15, 2026 | August 18, 2026 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Chief Medical Officer | August 06, 2019 | August 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date March 12, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,667 |
Reported balance
After 2026-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 16,667 · Balance 16,667 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 137,651 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 60,492 · Balance 137,651 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Sienna Biopharmaceuticals, Inc.
Report date August 06, 2019 · Filed August 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,488 |
Reported balance
After 2019-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-06 · Grant · Acquired 55,000 · Balance 196,488 F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.08 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-06 · Disposition to issuer · Disposed 48,720 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-07-26 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-08-06 · Disposition to issuer · Disposed 11,926 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-08-06 · Disposition to issuer · Disposed 14,904 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-08-06 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-08-06 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2027-07-26 | Direct | 11,926 |
Reported balance
After 2019-08-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-08-06 · Grant · Acquired 11,926 · Balance 11,926 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2028-06-01 | Direct | 48,720 |
Reported balance
After 2019-08-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-08-06 · Grant · Acquired 48,720 · Balance 48,720 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 14,904 |
Reported balance
After 2019-08-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-06 · Grant · Acquired 14,904 · Balance 14,904 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 22,500 |
Reported balance
After 2019-08-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-06 · Grant · Acquired 22,500 · Balance 22,500 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 22,500 |
Reported balance
After 2019-08-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-08-06 · Grant · Acquired 22,500 · Balance 22,500 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,557 |
Reported balance
Holding disclosure · report date 2019-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,557 F3: The shares are directly held by Lizzul Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
F2: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3: The shares are directly held by Lizzul Living Trust.
F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 60,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000014 · form4-08182026_040804.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,651 Underlying: Common Stock · 60,492 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 02, 2026 Filed Aug 5, 2026 22:25 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 60,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000011 · form4-08052026_100845.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,159 Underlying: Common Stock · 60,492 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 2, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 72,300 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001711462-26-000010 · form4-05142026_040501.xml · derivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,300 Underlying: Common Stock · 72,300 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 72,300 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 507,310 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000010 · form4-05142026_040501.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 21,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 12 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F8 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F12 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 25,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 11 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,575 Underlying: Common Stock · 25,575 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F8 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F11 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 21,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 10 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,110 Underlying: Common Stock · 21,110 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F8 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F10 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F10 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 9 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,145 Underlying: Common Stock · 6,145 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F8 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F9 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F9 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 8 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2036-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F6 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 97,200 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 7 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,200 Underlying: Common Stock · 97,200 shares Expires 2035-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 115,540 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 6 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,540 Underlying: Common Stock · 115,540 shares Expires 2034-01-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 67,070 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 5 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,070 Underlying: Common Stock · 67,070 shares Expires 2033-01-05 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 4 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 83,500 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001711462-26-000009 · form4-04222026_040419.xml · derivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires 2030-07-29 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 12, 2026 Filed Aug 7, 2026 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantPerformance Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000012 · form4-08072026_090818.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 00:16 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,650 | $44.71 | $163,191.50 |
DisclosureSEC source: 0001711462-26-000006 · form4-01102026_120159.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,088 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,235 | $45.11 | $100,820.85 |
DisclosureSEC source: 0001711462-26-000004 · form4-01082026_090121.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,213 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:16 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 8,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000006 · form4-01102026_120159.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,575 Underlying: Common Stock · 8,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:16 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 8,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001711462-26-000006 · form4-01102026_120159.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001711462-26-000004 · form4-01082026_090121.xml · derivative · entry 5 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2036-01-05 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 21,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000004 · form4-01082026_090121.xml · derivative · entry 4 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000004 · form4-01082026_090121.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,145 Underlying: Common Stock · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,145 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001711462-26-000004 · form4-01082026_090121.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 02:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,219 | $43.26 | $182,513.94 |
DisclosureSEC source: 0001711462-26-000002 · form4-01072026_020144.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,303 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 10,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001711462-26-000002 · form4-01072026_020144.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,110 Underlying: Common Stock · 10,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2026 Filed Jan 7, 2026 02:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001711462-26-000002 · form4-01072026_020144.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001711462-25-000003 · form4-12232025_091241.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 1,500 shares Expires 2030-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. F4 · balance_after: In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,500 | $50.00 | $75,000.00 |
DisclosureSEC source: 0001711462-25-000003 · form4-12232025_091241.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,967 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 1,500 | $18.50 | $27,750.00 |
DisclosureSEC source: 0001711462-25-000003 · form4-12232025_091241.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the acquisition of 1,324 shares acquired under the Company's ESPP. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 97,200 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · derivative · entry 8 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,200 Underlying: Common Stock · 97,200 shares Expires 2035-01-06 F8 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 34,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · derivative · entry 7 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,100 Underlying: Common Stock · 34,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · derivative · entry 6 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,290 Underlying: Common Stock · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 2,261 | $15.30 | $34,593.30 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · nonDerivative · entry 4 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,643 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,145 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · nonDerivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 10,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · derivative · entry 5 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,665 Underlying: Common Stock · 10,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 4,336 | $14.60 | $63,305.60 |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,759 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001046 · form4-01072025_100117.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 142 shares acquired under the Company's ESPP. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 20:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon · Derivative | 1,500 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001415889-24-023900 · form4-09242024_080920.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,000 Underlying: Common · 1,500 shares Expires 2030-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 85,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 20:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,500 | $38.67 | $58,005.00 |
DisclosureSEC source: 0001415889-24-023900 · form4-09242024_080920.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,398 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 20:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 1,500 | $18.50 | $27,750.00 |
DisclosureSEC source: 0001415889-24-023900 · form4-09242024_080920.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,220 | $38.93 | $86,424.60 |
DisclosureSEC source: 0001415889-24-023550 · form4-09172024_100907.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,398 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 22:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023550 · form4-09172024_100907.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 22:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-023550 · form4-09172024_100907.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon · Derivative | 2,000 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001415889-24-021452 · form4-08162024_080835.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,500 Underlying: Common · 2,000 shares Expires 2030-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 86,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,000 | $40.00 | $80,000.00 |
DisclosureSEC source: 0001415889-24-021452 · form4-08162024_080835.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,618 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 2,000 | $18.50 | $37,000.00 |
DisclosureSEC source: 0001415889-24-021452 · form4-08162024_080835.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020036 · form4-07242024_080712.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. F2 · derivative.expiration_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. Read SEC document |
| July 18, 2024 Filed Jul 20, 2024 00:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon · Derivative | 1,500 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001415889-24-019829 · form4-07202024_120740.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,500 Underlying: Common · 1,500 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F4 · balance_after: In addition to the remaining options to purchase 88,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms. Read SEC document |
| July 18, 2024 Filed Jul 20, 2024 00:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0001415889-24-019829 · form4-07202024_120740.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,618 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.